T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitis

人复发性扁桃体炎中滤泡辅助性 T (Tfh) CD4 T 细胞、生发中心和抗体反应功能障碍

• 批准号: 10169568
• 负责人: Shane P Crotty
• 金额: $ 38.62万
• 依托单位: LA JOLLA INSTITUTE FOR IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-26 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169568
• 关键词: 2019-nCoV; Antibody Response; Antigens; B-Lymphocytes; Bacteria; Biology; Bronchoalveolar Lavage; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 vaccine; Cells; Development; Disease; Epitopes; Functional disorder; Helper-Inducer T-Lymphocyte; Human; Immune response; Immunologics; Impairment; Infection; Intervention; Knowledge; Lung; Measures; Medical; Patients; Peptides; Peripheral Blood Mononuclear Cell; Phenotype; Recurrence; Resolution; Severity of illness; Structure of germinal center of lymph node; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; Techniques; Therapeutic; Tonsillitis; Vaccines; Virus; cost effective; cytokine; in vivo; innovation; pandemic disease; pathogen; response; therapy development

Overall Component COVID19 is a severe ongoing pandemic. Our understanding of the immune response to this disease is lacking, which impairs both the development of proper therapeutics and a vaccine. Vaccines are one of the most cost effective and extraordinarily successful medical interventions. Most of those vaccines depend on CD4 T+ cells and their help to B cells. We have developed multiple new techniques to study human CD4+ T cells over the past several years, which have have been implementing in our LJI CCHI. The supplement proposed here will facilitate rapid and vigorous pursuit of an understanding of the T cell responses to SARS-CoV2 in humans, which may help in the development of treatments and vaccines for COVID19.

整体组成 新冠肺炎 (COVID19) 是一场严重的持续流行病。我们对这种疾病的免疫反应缺乏了解， 这会损害适当的治疗方法和疫苗的开发。疫苗是最昂贵的之一 有效且非常成功的医疗干预措施。大多数疫苗依赖于 CD4 T+ 细胞 以及它们对 B 细胞的帮助。过去我们开发了多种新技术来研究人类 CD4+ T 细胞 几年来，我们的 LJI CCHI 一直在实施。这里提出的补充将有助于 快速而积极地了解人类 T 细胞对 SARS-CoV2 的反应，这可能 帮助开发新冠病毒 (COVID19) 的治疗方法和疫苗。